1. Executive Session  6:00 - 6:15
   - Discussion on Medicaid OBRA’90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes  6:15 - 6:20
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates  6:20 - 6:25
   - Updates

4. Medical Director Update  6:25 - 6:30
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings  6:30 – 6:40
   - New Cholesterol Treatment Guidelines

6. RetroDUR/DUR  6:40 – 7:20
   - Oxycodone IR/Hydromorphone IR Retrospective Drug Utilization Review

7. Clinical Update: Drug Reviews  7:20 – 7:50
   (Public comment prior to Board action)
   **Abbreviated New Drug Reviews**
   - Oxytrol® (oxybutynin transdermal system) OTC
   - Vecamyl® (mecamylamine) Oral Tablet

   **Full New Drug Reviews**
   - Breo Ellipta® (fluticasone furoate and vilanterol inhalation powder) Inhaler
   - Olysio® (simeprevir) Oral Capsule
   - Sovaldi® (sofosbuvir) Oral Tablet

8. Clinical Update: New/Updated Clinical Guidelines  7:50 – 8:00
   (Public comment prior to Board action)
   - JNC 8 Hypertension Guidelines

9. Therapeutic Drug Classes – Periodic Review  8:00 – 8:00
   (Public comment prior to Board action)
   - None
10. New Managed Therapeutic Drug Classes 8:00–8:00
   (Public comment prior to Board action)
   - None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:00–8:10
   (Public comment prior to Board action)
   - Anti-Hyperkinesis and Anti-Narcolepsy/Cataplexy
   - Ilaris® (canakinumab) Injection in SJIA (new FDA approved diagnosis)
   - Miscellaneous: Soliris® (eculizumab)

12. General Announcements 8:10–8:15
   Selected FDA Safety Alerts
   - Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement - Recommendation to Discontinue Prescribing and Dispensing
   - Onfi® (clobazam): Drug Safety Communication - Risk of Serious Skin Reactions

13. Adjourn 8:15